Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 96 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H1 2015', provides an overview of the Anaplastic Large Cell Lymphoma (ALCL)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anaplastic Large Cell Lymphoma (ALCL)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Anaplastic Large Cell Lymphoma (ALCL) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Anaplastic Large Cell Lymphoma (ALCL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anaplastic Large Cell Lymphoma (ALCL) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anaplastic Large Cell Lymphoma (ALCL)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anaplastic Large Cell Lymphoma (ALCL) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Anaplastic Large Cell Lymphoma (ALCL) Overview 7
Therapeutics Development 8
Pipeline Products for Anaplastic Large Cell Lymphoma (ALCL) - Overview 8
Pipeline Products for Anaplastic Large Cell Lymphoma (ALCL) - Comparative Analysis 9
Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics under Development by Companies 10
Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics under Investigation by Universities/Institutes 12
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Anaplastic Large Cell Lymphoma (ALCL) - Products under Development by Companies 16
Anaplastic Large Cell Lymphoma (ALCL) - Products under Investigation by Universities/Institutes 17
Anaplastic Large Cell Lymphoma (ALCL) - Companies Involved in Therapeutics Development 18
Akron Molecules AG 18
AstraZeneca PLC 19
Bayer AG 20
Celon Pharma Sp. z o.o. 21
Pfizer Inc. 22
Sareum Holdings plc 23
Seattle Genetics, Inc. 24
Sigma-Tau S.p.A. 25
Teva Pharmaceutical Industries Limited 26
Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
AKR-303 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
AZD-3463 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
brentuximab vedotin - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
CEP-28122 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
CEP-37440 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
copanlisib - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
crizotinib - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Drug to Inhibit ALK for Anaplastic Large Cell Lymphoma - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
KRA-0008 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
pegaspargase - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
SH-7129 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecules to Inhibit Aurora and ALK Kinase for Oncology - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Anaplastic Large Cell Lymphoma (ALCL) - Recent Pipeline Updates 58
Anaplastic Large Cell Lymphoma (ALCL) - Dormant Projects 78
Anaplastic Large Cell Lymphoma (ALCL) - Discontinued Products 79
Anaplastic Large Cell Lymphoma (ALCL) - Product Development Milestones 80
Featured News & Press Releases 80
Dec 07, 2014: Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting 80
Dec 06, 2014: Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting 81
Nov 07, 2014: Seattle Genetics to Present Clinical Data from Broad ADCETRIS (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014 83
Nov 06, 2014: Takeda Announces Abstracts for ADCETRIS (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma to be Presented at 56th American Society of Hematology Annual Meeting 85
Sep 24, 2014: Seattle Genetics Highlights Updated Progression-Free Survival and Overall Survival Data from ADCETRIS (Brentuximab Vedotin) Frontline PTCL Phase 1 Clinical Trial at the ESMO 2014 Congress 86
Apr 17, 2014: ADCETRIS 50mg for intravenous drip infusion", Treatment for Patients with CD30 Positive Relapsed or Refractory Hodgkin Lymphoma or Relapsed or Refractory Anaplastic Large Cell Lymphoma Now Available in Japan 88
Jan 17, 2014: Seattle Genetics Announces ADCETRIS Approval in Japan for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma 88
Jun 21, 2013: Seattle Genetics Highlights Adcetris Clinical Data At International Conference On Malignant Lymphoma 89
Jun 19, 2013: Takeda And Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival With Adcetris At International Conference On Malignant Lymphoma 91
Jun 01, 2013: Takeda Highlights Data From Phase I/II Clinical Trial Examining Use Of Adcetris in Pediatric Patients With Hodgkin Lymphoma Or Systemic Anaplastic Large Cell Lymphoma 93
Appendix 95
Methodology 95
Coverage 95
Secondary Research 95
Primary Research 95
Expert Panel Validation 95
Contact Us 95
Disclaimer 96

List of Tables
Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL), H1 2015 8
Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL) - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Investigation by Universities/Institutes, H1 2015 17
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Akron Molecules AG, H1 2015 18
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by AstraZeneca PLC, H1 2015 19
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Bayer AG, H1 2015 20
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Celon Pharma Sp. z o.o., H1 2015 21
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Pfizer Inc., H1 2015 22
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Sareum Holdings plc, H1 2015 23
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Seattle Genetics, Inc., H1 2015 24
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Sigma-Tau S.p.A., H1 2015 25
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 26
Assessment by Monotherapy Products, H1 2015 27
Number of Products by Stage and Target, H1 2015 29
Number of Products by Stage and Mechanism of Action, H1 2015 31
Number of Products by Stage and Route of Administration, H1 2015 33
Number of Products by Stage and Molecule Type, H1 2015 35
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics - Recent Pipeline Updates, H1 2015 58
Anaplastic Large Cell Lymphoma (ALCL) - Dormant Projects, H1 2015 78
Anaplastic Large Cell Lymphoma (ALCL) - Discontinued Products, H1 2015 79